The failure of torcetrapib: is there a case for independent preclinical and clinical testing? – author's reply

By Doggrell Sheila A  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 14, 2008-10 ,pp. : 2563-2564

Informa Healthcare

Access to resources Recommend Favorite

Aurora kinase inhibitors in preclinical and clinical testing

By Cheung Chun Hei Antonio   Coumar Mohane Selvaraj   Hsieh Hsing-Pang   Chang Jang-Yang  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 379-398

Informa Healthcare

Access to resources Recommend Favorite

Zebrafish As a Genetic Model in Pre-Clinical Drug Testing and Screening

By  

Current Medicinal Chemistry, Vol. 20, Iss. 19, 2013-06 ,pp. : 2458-2466

Bentham Science Publishers

Access to resources Recommend Favorite

The Timing of Preclinical Toxicological Studies: Pharmaceutical Company Approaches to Toxicity Testing in Support of Initial Clinical Investigations

By Parkinson C.   Thomas K.E.   Lumley C.E.  

Regulatory Toxicology and Pharmacology, Vol. 23, Iss. 2, 1996-04 ,pp. : 162-172

Academic Press

Access to resources Recommend Favorite

Clinical and Preclinical Pharmacokinetics of Raltitrexed

By Clarke S.J.  

Clinical Pharmacokinetics, Vol. 39, Iss. 6, 2000-12 ,pp. : 429-443

Adis International

Access to resources Recommend Favorite